Delivering innovation proactively and with fairness, integrity and pragmatism
Alan Hale - CEO
Alan has over 35 years’ industrial experience in biotech and technology working in a range of commercial (large, SME and start-up), academic and public sector organisations. He started his career in big pharma before moving into biotechnology. He has directed Research and Development in life sciences, enabling technologies and energy sectors and in technology areas as diverse as synthetic biology, pharmaceuticals, genetics and text analytics.
Alan is experienced in developing new companies in the early stages and in raising finance. His breadth of experience in a range of industry sectors and types plus his hands-on operational knowledge of how to make an organisation work effectively, combines well with his experience working with entrepreneurs and early stage technologies. This expertise provides for a strong strategic focus in Biotangents and his clear vision, balanced with the understanding of how teams can deliver on the ground, is supported by his strong people skills.
Alan contributed in an advisory capacity to the development of Biotangents from its embryonic stage and formally joined the company as CEO in November 2016.
Lina completed her undergraduate studies in Molecular Biology at Vilnius University and holds an MSc in Biotechnology from the University of Edinburgh. As part of her research, she incorporated standardisation into a proprietary combinatorial DNA assembly technology, making it compatible with the widely used BioBrick™ standard. Lina also acted as an adviser to the University of Edinburgh’s 2013 gold medal-winning iGEM team. After graduation, Lina continued to work in DNA manipulation and metabolic engineering of bacteria, delivering varied projects with local SMEs and multinational partners.
Dr Andy Hall-Ponselè - Director of Operations
Andy designed the Leapfrog Assembly™ technology upon which Biotangents was founded and led the successful project to apply it to the biosynthesis of high-value terpenoids. He now leads operations at Biotangents and is part of an ambitious team that has secured and fulfilled multiple contracts to perform DNA manipulation work for industrial and academic customers.
Andy has been involved in synthetic biology since 2008 when, as a student under Professor Chris French, he led the University of Edinburgh iGEM team to a gold medal. He holds a DPhil from the University of Oxford, where he used metabolic engineering approaches to provide new insights into the control of metabolism in plants. On his return to Edinburgh, Andy worked as a Senior Scientist in a University of Edinburgh-based start-up, delivering collaborative projects as varied as synthetic promoter design and polysaccharide biosynthesis.